The study covered in this summary was published on Research Square as a preprint and has not yet been peer reviewed. Anaplastic thyroid cancer is a rare thyroid malignancy; disease-specific mortality ...

Two prospective trials of immunotherapy in thyroid cancer, one of them negative, provided support for precision-medicine approaches that include immunotherapy. The studies were reported simultaneously ...

Breast implant–associated anaplastic large-cell lymphoma (BI-ALCL) is a rare type of T-cell lymphoma that arises around breast implants. The optimal management of this disease has not been established ...

Anaplastic sarcoma of the kidney presents as a large renal mass, and its major gross and histologic features include the presence of cysts, marked anaplasia in the spindle cell component, and areas of ...

DelveInsight’s, “Anaplastic Thyroid Cancer Pipeline Insight 2025,” report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Anaplastic Thyroid Cancer pipeline landscape. It ...

A collaboration between scientists from St. Jude Children's Research Hospital and Dana-Farber Cancer Institute uncovered four proteins that govern the identity of anaplastic large cell lymphoma (ALCL) ...

Phase IIa Study of PLX2853 in Gynecologic Cancers With Known ARID1A Mutation and Phase Ib/IIa Study of PLX2853/Carboplatin in Platinum-Resistant Epithelial Ovarian Cancer Adult-onset neuroblastoma ...

Please provide your email address to receive an email when new articles are posted on . An updated guideline for best practices in managing anaplastic thyroid cancer stresses the need for ...

Anaplastic thyroid cancer is the rarest type of thyroid cancer and the most challenging to treat. Anaplastic thyroid cancer cases are only 1% of all thyroid cancer cases, and the cure rate is low. The ...

Medullary Thyroid Cancer - For the most part, when people think of thyroid cancer, they think of an easily treatable disease. The reality of the matter is that this is seldomly the case. Thyroid ...

The major anaplastic lymphoma kinase inhibitors market growth came from second-generation ALK inhibitors segment. The high prevalence of lung cancer, strong pipeline development, and recent approvals ...